Nanobiotix stock lagging in SBF 120 despite +324% over one year

A decline of 6.15% that brings the stock back towards its 20-day moving average

Nanobiotix is down 6.15% to €35.70 during trading, after closing at €38.04 on Friday. The decline is sharp, but the stock remains above its 20-day MA at €34.39 (a gap of +3.81%), which tempers the extent of the pullback in short-term momentum. It also remains well above its 50-day MA at €33.43, representing a gap of +6.79%.

These two moving averages had already provided support during the summer rebound: in late July, the stock had hit resistance at the 20-day MA following a 4% rebound, before breaking through it. The RSI at 63, in positive territory without signaling an extreme configuration, does not indicate structural buyer exhaustion. The support zone at €31.28 remains far from the current price; resistance at €38.12, on the other hand, roughly corresponds to the last close, suggesting that the stock is encountering this ceiling again.

An annual performance of +324% that puts today's move into longer-term perspective

Despite today's decline, Nanobiotix's trajectory over one year remains exceptional: the stock is up +324% over twelve months, and the past week remains positive at +10.53%. Today's pullback is thus occurring in a stock that has advanced substantially over the past year, supported by clinical advances in NBTXR3 (co-developed with Johnson & Johnson under the name JNJ-1900). When publishing first quarter 2026 results on June 2, 2026, the company highlighted the progress of clinical studies on JNJ-1900 and the strengthening of the Nanoprimer platform as growth drivers, while noting among risks the still limited progress in the standard of care for inoperable NSCLC.
Resistance at €38.12 now constitutes the key level to watch for validating or denying a return towards recent highs.